THAR fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
THAR does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company